Accordingly, the main purpose of this study was to engineer a chimeric HMGB1‐specific mAb with the potential to be evaluated in future clinical trials, by investigating its therapeutic efficacy in a previously shown HMGB1‐dependent experimental model of APAP‐ALI. The gene discussed is HMGB1; the disease is acute respiratory distress syndrome.